We are live on ! Find out more
CTNM

Contineum Therapeutics
CTNM

63 hedge funds and large institutions have $107M invested in Contineum Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

2% more funds holding

Funds holding: 62 → 63 (+1)

6% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 18

2.98% less ownership

Funds ownership: 82.87% → 79.89% (-3%)

54% less capital invested

Capital invested by funds: $231M → $107M (-$124M)

Holders
63
Holders Change
+1
Holders Change %
+1.61%
% of All Funds
0.84%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
6
Increased
19
Reduced
18
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$1.19M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.08M
3
ACM
ADAR1 Capital Management
Texas
+$787K
4
Morgan Stanley
Morgan Stanley
New York
+$278K
5
Marshall Wace
Marshall Wace
United Kingdom
+$184K

Top Sellers

Rank Fund Capital Flow
1
SC
Stempoint Capital
New York
-$3.89M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.93M
3
CC
Casdin Capital
New York
-$1.35M
4
Squarepoint
Squarepoint
New York
-$784K
5
PCH
Polar Capital Holdings
United Kingdom
-$639K
Name Holding Trade Value Shares
Change 		Change in
Stake
JJ
1
Johnson & Johnson
New Jersey
$13.8M – – –
SCM
2
Suvretta Capital Management
New York
$12M – – –
Franklin Resources
3
Franklin Resources
California
$11M +$1.19M +130,616 +9%
PA
4
Perceptive Advisors
New York
$10.1M – – –
VVM
5
Versant Venture Management
California
$6.41M – – –
Fidelity Investments
6
Fidelity Investments
Massachusetts
$5.66M +$1.08M +118,436 +17%
Vanguard Group
7
Vanguard Group
Pennsylvania
$5.61M -$51.4K -5,655 -0.7%
SAM
8
Sectoral Asset Management
Quebec, Canada
$5.59M – – –
HA
9
HHLR Advisors
Cayman Islands
$4.67M – – –
RTM
10
Red Tree Management
California
$4.45M – – –
BlackRock
11
BlackRock
New York
$4.3M +$119K +13,047 +2%
SB
12
Samsara BioCapital
California
$4.11M – – –
SVCM
13
Saturn V Capital Management
Texas
$3.92M -$110K -12,043 -2%
BBA
14
Baker Bros. Advisors
New York
$2.18M – – –
ACM
15
Altium Capital Management
New York
$2.12M -$274K -30,143 -9%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.35M +$42.2K +4,643 +2%
Norges Bank
17
Norges Bank
Norway
$1.18M – – –
ACM
18
ADAR1 Capital Management
Texas
$1.18M +$787K +86,531 +105%
CC
19
Casdin Capital
New York
$1.04M -$1.35M -148,333 -50%
SSA
20
Schonfeld Strategic Advisors
New York
$993K +$147K +16,205 +13%
Squarepoint
21
Squarepoint
New York
$915K -$784K -86,212 -40%
State Street
22
State Street
Massachusetts
$886K +$19.3K +2,120 +2%
Northern Trust
23
Northern Trust
Illinois
$584K -$51.3K -5,636 -6%
Morgan Stanley
24
Morgan Stanley
New York
$399K +$278K +30,601 +115%
Charles Schwab
25
Charles Schwab
California
$357K -$37.5K -4,128 -7%
1
2 3

CTNM Hedge Fund Activity: Q1 2025 in Review

63 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q1 2025, worth a combined $107M — down 54% from $231M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CTNM positions and 5 closed out — a net gain of 1 holder — while 19 added to existing stakes and 18 trimmed.

The largest buyer was Franklin Resources, adding an estimated $1.19M. The largest seller was Stempoint Capital, exiting entirely with an estimated $3.89M sold.

  • 63 institutional investors held Contineum Therapeutics (CTNM) as of Q1 2025, up from 62 in Q4 2024.
  • Funds reported $107M of Contineum Therapeutics stock for Q1 2025, down 54% quarter-over-quarter.
  • 6 funds opened new Contineum Therapeutics positions in Q1 2025 and 5 closed out, a net change of +1 holder.
  • The largest Contineum Therapeutics buyer in Q1 2025 was Franklin Resources, an estimated $1.19M added.
  • The largest Contineum Therapeutics seller in Q1 2025 was Stempoint Capital, an estimated $3.89M sold.

Based on aggregated 13F filings for Q1 2025.